Original release date: November 5, 2020
Access to this course expires on: May 5, 2021 at 11:59 PM Pacific Time
This session reviews uterine mesenchymal tumors with deceptively bland morphology that mimic variants of leiomyoma yet may carry malignant potential (inflammatory myofibroblastic tumor, PEComa, NTRK fusion sarcoma), recurrent potential (leiomyoma with bizarre nuclei) or risk for hereditary syndrome (tuberous sclerosis complex, hereditary leiomyoma renal cell carcinoma syndrome). A pattern-based approach (spindle cell pattern, epithelioid pattern, myxoid pattern) will be used to provide practical strategies for morphologic evaluation and for selection of immunohistochemical and molecular tests.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships: Joseph T. Rabban, MD, MPH: Spouse Employee, Merck and Co.
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.